Pharmaceuticals · Nasdaq · #47 by market cap (snapshot)
Sanofi (ADS)
Price data: TradingView widget below
Loading chart…
Loading chart…
📐 Technicals
Loading chart…
Indicator summary from TradingView (moving averages, oscillators). A mechanical signal, not advice.
📊 Fundamentals
Loading chart…
🏢 Company profile
Loading chart…
📰 Latest SNY news
Loading chart…
🧩 What it is
Sanofi is a French pharma giant making medicines and vaccines. Its blockbuster is Dupixent for eczema and asthma. On Nasdaq it trades as ADS.
⚡ Why it's interesting
Dupixent sales have been growing fast, and vaccines provide steady business. It pays a dividend.
⚠️ Key risks
It depends a lot on one drug, whose patents won't last forever. Pipeline setbacks happen, euro/dollar moves matter for ADS holders, and drug pricing is politically sensitive.
👀 What to watch
Dupixent growth, pipeline news and currency. A European pharma giant with US-listed shares. Immunology is where most of its growth hopes sit.
Written by the Hodlia.fi editorial team. Education only — not financial advice, no price predictions.
❓ Sanofi (ADS) FAQ
What is Sanofi (ADS) (SNY)?
Sanofi is a French pharma giant making medicines and vaccines. Its blockbuster is Dupixent for eczema and asthma. On Nasdaq it trades as ADS.
Why do people follow Sanofi (ADS)?
Dupixent sales have been growing fast, and vaccines provide steady business. It pays a dividend.
What are the main risks of Sanofi (ADS)?
It depends a lot on one drug, whose patents won't last forever. Pipeline setbacks happen, euro/dollar moves matter for ADS holders, and drug pricing is politically sensitive.
What should I watch with Sanofi (ADS)?
Dupixent growth, pipeline news and currency. A European pharma giant with US-listed shares. Immunology is where most of its growth hopes sit.
Is Sanofi (ADS) a good investment?
Hodlia doesn't give investment advice. Whether Sanofi (ADS) fits you depends on your goals, time horizon and how much loss you can handle. Single stocks can drop a lot even when markets are calm. Read the risks above, compare with a diversified alternative and consider independent advice.